Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 203

Next Previous
Drug Profile

IMA 203

Alternative Names: IMA-203; IMA203-GEN1

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immatics US
  • Developer Bristol-Myers Squibb; Immatics US; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase I Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 31 May 2025 Efficacy and adverse event data from an extended phase Ib portion of phase I ACTengine trial in Solid tumours released by Immatics
  • 13 May 2025 Immatics announces intention to submit BLA for Malignant melanoma in first quarter of 2027
  • 28 Apr 2025 Immatics in collaboration with Moderna plans a phase I trial for Melanoma and Sarcoma (Metastatic disease, Unresectable/Inoperable, Second-line therapy or greater, Combination therapy) in April 2025 (NCT06946225)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top